Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Orbital Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://orbitaltx.com
Year Founded: 2022
Status: Private
See Emerging Company Profile .
BioCentury | Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
BioCentury | Nov 21, 2024
Management Tracks
Amgen names Howard Chang head of research and CSO
Plus: Head of R&D Blackman retires from Day One, and updates from Karyopharm and L.E.K.
BioCentury | Oct 11, 2024
Finance
City is location of Maraganore’s next RNAi play
BioCentury’s latest Venture Report includes rounds for Judo, Purespring, Basecamp, Arda and more
BioCentury | Sep 10, 2024
Management Tracks
Lucas Montarce named Lilly CFO
Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more
BioCentury | Sep 5, 2024
Management Tracks
Pfizer names Elif Aral president of MERA
Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more
BioCentury | Jun 26, 2024
Discovery & Translation
Lurie winner Chang: Translating the unexpected in gene regulation
A Q&A with the serial entrepreneur, who was awarded FNIH’s Lurie Prize for his lncRNA
BioCentury | Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
BioCentury | Oct 2, 2023
Product Development
Karikó, Weissman awarded Nobel Prize for mRNA discovery
Penn researchers were behind mRNA COVID-19 vaccines
BioCentury | Aug 17, 2023
Product Development
Emerging circular RNA field split on what to deliver and how to deliver it
The rising therapeutic modality is more durable than linear mRNA, promising efficacy and manufacturing advantages
BioCentury | May 26, 2023
Data Byte
The 20 biggest venture raises year-to-date: genetic medicines dominate
Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines
Items per page:
1 - 10 of 15